Shares of Inspire Medical Systems, Inc. (NYSE:INSP – Get Rating) have been assigned an average rating of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $312.56.
A number of analysts have recently weighed in on INSP shares. 92 Resources reaffirmed a “maintains” rating on shares of Inspire Medical Systems in a research report on Wednesday, May 3rd. Stifel Nicolaus boosted their price target on Inspire Medical Systems from $290.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Mizuho started coverage on Inspire Medical Systems in a research note on Thursday, April 13th. They issued a “buy” rating and a $300.00 price target on the stock. Truist Financial lifted their price objective on Inspire Medical Systems from $335.00 to $360.00 in a research note on Thursday, May 18th. Finally, UBS Group increased their price objective on shares of Inspire Medical Systems from $300.00 to $304.00 in a research report on Wednesday, May 3rd.
In other news, VP Steven Jandrich sold 8,000 shares of the business’s stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $271.02, for a total transaction of $2,168,160.00. Following the sale, the vice president now directly owns 4,371 shares of the company’s stock, valued at $1,184,628.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Inspire Medical Systems news, Director Jerry C. Griffin sold 529 shares of the stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $280.00, for a total transaction of $148,120.00. Following the transaction, the director now owns 3,200 shares in the company, valued at $896,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Steven Jandrich sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 25th. The stock was sold at an average price of $271.02, for a total value of $2,168,160.00. Following the transaction, the vice president now directly owns 4,371 shares of the company’s stock, valued at $1,184,628.42. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,310 shares of company stock worth $4,280,627. Company insiders own 4.50% of the company’s stock.
Institutional Investors Weigh In On Inspire Medical Systems
Inspire Medical Systems Trading Up 0.3 %
Shares of INSP opened at $299.88 on Thursday. The stock has a 50-day moving average price of $263.40 and a 200-day moving average price of $252.25. The company has a market cap of $8.70 billion, a PE ratio of -192.23 and a beta of 1.44. Inspire Medical Systems has a 12-month low of $157.04 and a 12-month high of $314.36.
Inspire Medical Systems (NYSE:INSP – Get Rating) last announced its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.17. Inspire Medical Systems had a negative return on equity of 10.27% and a negative net margin of 9.35%. The business had revenue of $127.90 million for the quarter, compared to analysts’ expectations of $120.06 million. During the same period in the previous year, the firm earned ($0.61) EPS. The business’s quarterly revenue was up 84.3% on a year-over-year basis. As a group, analysts predict that Inspire Medical Systems will post -1.18 earnings per share for the current year.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead.
- Get a free copy of the StockNews.com research report on Inspire Medical Systems (INSP)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.